• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    3/2/23 12:31:10 PM ET
    $BPTS
    $BRTX
    $CANO
    $IBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Managed Health Care
    Health Care
    Get the next $BPTS alert in real time by email

    Gainers

    • BioRestorative Therapies (NASDAQ:BRTX) stock rose 32.4% to $3.69 during Thursday's regular session. BioRestorative Therapies's stock is trading at a volume of 28.4 million shares as of 12:30 EST. This is 189085.2% of its average full-day volume over the last 100 days. The company's market cap stands at $13.5 million.
    • OncoSec Medical (NASDAQ:ONCS) shares rose 19.6% to $2.44. The current volume of 31.8 million shares is 2304.3% of OncoSec Medical's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $7.2 million.
    • Biophytis (NASDAQ:BPTS) stock moved upwards by 19.56% to $0.5. The current volume of 7.6 million shares is 1275.2% of Biophytis's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $10.1 million.
    • Owlet (NYSE:OWLT) shares moved upwards by 16.63% to $0.42. Owlet's stock is trading at a volume of 1.3 million shares as of 12:30 EST. This is 177.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $48.6 million.
    • MultiPlan (NYSE:MPLN) shares rose 14.73% to $1.03. Trading volume for MultiPlan's stock is 1.5 million as of 12:30 EST. This is 81.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $699.0 million. As per the press release, Q4 earnings came out 2 days ago.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 14.68% to $0.14. As of 12:30 EST, Novo Integrated Sciences's stock is trading at a volume of 25.6 million, which is 160.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.1 million.

    Losers

    • ZimVie (NASDAQ:ZIMV) shares declined by 36.0% to $6.69 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume of 3.9 million shares, making up 885.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $174.5 million. As per the news, the Q4 earnings report came out yesterday.
    • Lucira Health (NASDAQ:LHDX) stock declined by 28.45% to $0.57. Trading volume for this security as of 12:30 EST is 27.0 million, which is 142.0% of its average full-day volume over the last 100 days. The company's market cap stands at $22.9 million.
    • Cano Health (NYSE:CANO) stock fell 19.43% to $1.26. Trading volume for this security as of 12:30 EST is 15.3 million, which is 169.6% of its average full-day volume over the last 100 days. The company's market cap stands at $302.5 million. As per the news, the Q4 earnings report came out yesterday.
    • Ontrak (NASDAQ:OTRKP) shares decreased by 19.4% to $0.81.
    • ImmunityBio (NASDAQ:IBRX) shares fell 15.64% to $1.92. As of 12:30 EST, ImmunityBio's stock is trading at a volume of 3.4 million, which is 165.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $803.1 million.
    • Societal CDMO (NASDAQ:SCTL) stock fell 13.9% to $1.24. Trading volume for this security as of 12:30 EST is 3.2 million, which is 2150.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $104.8 million. As per the press release, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BPTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BPTS
    $BRTX
    $CANO
    $IBRX

    CompanyDatePrice TargetRatingAnalyst
    Owlet Inc.
    $OWLT
    12/9/2025Outperform
    William Blair
    ZimVie Inc.
    $ZIMV
    7/31/2025$19.00Buy → Neutral
    B. Riley Securities
    ZimVie Inc.
    $ZIMV
    7/22/2025$19.00Underweight → Equal Weight
    Barclays
    ImmunityBio Inc.
    $IBRX
    5/20/2025$5.00Neutral → Overweight
    Piper Sandler
    Owlet Inc.
    $OWLT
    4/23/2025$7.00Outperform
    Northland Capital
    ZimVie Inc.
    $ZIMV
    4/10/2025$16.00Buy
    B. Riley Securities
    ZimVie Inc.
    $ZIMV
    3/13/2025Buy → Hold
    Needham
    ImmunityBio Inc.
    $IBRX
    3/6/2025$8.00Buy
    H.C. Wainwright
    More analyst ratings

    $BPTS
    $BRTX
    $CANO
    $IBRX
    SEC Filings

    View All

    SEC Form S-8 filed by Owlet Inc.

    S-8 - Owlet, Inc. (0001816708) (Filer)

    3/9/26 9:46:54 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    SEC Form 10-K filed by Owlet Inc.

    10-K - Owlet, Inc. (0001816708) (Filer)

    3/9/26 4:34:26 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    Owlet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Owlet, Inc. (0001816708) (Filer)

    3/5/26 4:07:49 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    $BPTS
    $BRTX
    $CANO
    $IBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Owlet Reports Fourth Quarter and Full Year 2025 Results; Initiates 2026 Guidance

    Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today reports financial results for the fourth quarter and full year ended December 31, 2025. Owlet's President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company's results and provide a business update today, March 5, 2026, at 4:30 p.m. ET. Q4 2025 Financial Highlights: Q4 Revenue of $26.6 million, up 29.6% from Q4 2024 Q4 Gross Profit of $12.6 million, up $1.7 million from Q4 2024 despite tariff cost impacts; Q4 Gross Margin of 47.6% Q4 Operating Loss of $4.9 million, compared to operating lo

    3/5/26 4:05:00 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

    Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that members of its commercial leadership team will participate in the Be+Well Beauty and Wellness Show taking place March 8-10, 2026 at the Javits Center in New York City. The Be+Well trade show is one of the largest professional beauty, spa, and wellness trade events in the U.S., bringing together 35,000+

    3/5/26 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy

    Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build momentum MELVILLE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today issued the following letter to shareholders from Chief Executive Officer Lance Alstodt: To our shareholders and stakeholders, The first quarter of 2026 marks a pivotal period for BioRestorative Therapies. We have achie

    3/4/26 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BPTS
    $BRTX
    $CANO
    $IBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Simon Barry J. sold $900,788 worth of shares (75,000 units at $12.01), decreasing direct ownership by 3% to 2,850,821 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/26/26 8:12:26 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Selecky Christobel exercised 25,000 shares at a strike of $2.98 and sold $250,000 worth of shares (25,000 units at $10.00) (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:58 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Soon-Shiong Patrick converted options into 114,329 shares and covered exercise/tax liability with 58,170 shares, increasing direct ownership by 0.19% to 29,757,911 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:07 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BPTS
    $BRTX
    $CANO
    $IBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Owlet

    William Blair initiated coverage of Owlet with a rating of Outperform

    12/9/25 8:52:06 AM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    ZimVie downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded ZimVie from Buy to Neutral and set a new price target of $19.00

    7/31/25 7:17:57 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie upgraded by Barclays with a new price target

    Barclays upgraded ZimVie from Underweight to Equal Weight and set a new price target of $19.00

    7/22/25 10:21:16 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $BPTS
    $BRTX
    $CANO
    $IBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Information Officer Kim Michael bought $249,588 worth of shares (40,000 units at $6.24), increasing direct ownership by 3% to 1,312,772 units (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    11/19/24 4:35:27 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    SVP, Corp. Affairs/Strategy Mintz William B. bought $104,359 worth of shares (278,165 units at $0.38), increasing direct ownership by 14% to 2,206,736 units (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    8/8/24 4:30:55 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Pres., Chief Executive Officer Dalton Travis bought $185,000 worth of shares (500,000 units at $0.37), increasing direct ownership by 11% to 5,004,504 units (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    8/7/24 6:05:14 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    $BPTS
    $BRTX
    $CANO
    $IBRX
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

    MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today its hiring of Industry leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative domestically and internationally, as well as providing new product and sales expertise to the Company. Mr. Lipkins has an accom

    6/10/25 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BPTS
    $BRTX
    $CANO
    $IBRX
    Financials

    Live finance-specific insights

    View All

    Owlet Reports Fourth Quarter and Full Year 2025 Results; Initiates 2026 Guidance

    Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today reports financial results for the fourth quarter and full year ended December 31, 2025. Owlet's President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company's results and provide a business update today, March 5, 2026, at 4:30 p.m. ET. Q4 2025 Financial Highlights: Q4 Revenue of $26.6 million, up 29.6% from Q4 2024 Q4 Gross Profit of $12.6 million, up $1.7 million from Q4 2024 despite tariff cost impacts; Q4 Gross Margin of 47.6% Q4 Operating Loss of $4.9 million, compared to operating lo

    3/5/26 4:05:00 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Owlet to Report Fourth Quarter and Full Year 2025 Financial Results on March 5, 2026

    Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, plans to announce fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Owlet's President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call at 4:30 p.m. ET the same day to discuss these results and provide a business update. Participants may access the call at 833-470-1428 (domestic) or 646-844-6383 (international) and reference Access Code 211338. A simultaneous webcast may be accessed online at the Events section of Owlet's Investor Relations website at investors.owletcare.com.

    2/19/26 4:05:00 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    $BPTS
    $BRTX
    $CANO
    $IBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ZimVie Inc.

    SC 13G - ZimVie Inc. (0001876588) (Subject)

    11/14/24 4:11:11 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    11/14/24 10:58:06 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by MultiPlan Corporation

    SC 13G/A - MultiPlan Corp (0001793229) (Subject)

    11/12/24 4:00:27 PM ET
    $MPLN
    Business Services
    Consumer Discretionary